Predicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte ratio
Predicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte ratio
复制标题
DOI：
10.1007/s00277-013-1978-8
复制
发表时间：
2014-05-01
影响因子：
3.5
通讯作者：
Turgut, Mehmet
中科院分区：
文献类型：
--
作者：
Kelkitli, Engin;Atay, Hilmi;Turgut, Mehmet
诊断时的中性粒细胞/淋巴细胞比率(NLR)已被证明是实体瘤患者生存的一个预后因素。诊断时NLR作为多发性骨髓瘤(MM)预后因素的研究尚未见报道。因此，研究的重点是NLR与已证实的MM患者预后参数的相关性。共有151名符合国际骨髓瘤工作组(IMWG)标准的MM患者通过回顾患者的记录进入研究。150名年龄和性别匹配的健康对照组也包括在这项研究中。使用从全血细胞计数(CBC)获得的数据计算NLR。MM组NLR值明显高于对照组(P<0.0001)。在这项研究中，存活患者的中位随访期为41个月。通过单因素和多因素分析发现，诊断时NLR是总生存期(OS)和无事件生存期(EFS)的独立预测因子。与确诊时患有nlr<；2的患者相比，nlr<；2的患者具有更好的OS(5年OS率分别为87.5%和42.4%；p<；0.0001)。以类似的方式，与诊断时NLRa为千分之2的患者相比，NLR2患者的EFS更好(5年EFS率分别为88.4%和41.8%，p<；0.0001)。这项研究表明，诊断时NLR是评估MM患者临床结果的一种简单、廉价、可能的预后因素。
The neutrophil/lymphocyte ratio (NLR) at diagnosis has been shown to be a prognostic factor for survival in solid tumors. The NLR at diagnosis as a prognostic factor for multiple myeloma (MM) has not been studied. Therefore, the focus of the study was the correlation of NLR with the proven prognostic parameters in patients with MM. A total of 151 MM patients who fulfilled the International Myeloma Working Group (IMWG) criteria were enrolled in the study by a retrospective review of the patients' records. One hundred fifty-one age- and gender-matched healthy controls were also included in the study. NLR was calculated using data obtained from the complete blood count (CBC). NLR was significantly higher in MM patients than the control group (2.79 +/- 1.82 vs. 1.9 +/- 0.61, respectively; p < 0.0001). The median follow-up on living patients in this study was 41 months. NLR at the diagnosis was found to be an independent predictor for overall survival (OS) and event-free survival (EFS) by univariate and multivariate analysis. Patients with a NLR < 2 at diagnosis experienced superior OS compared with patients with a NLR a parts per thousand yen2 (5-year OS rates were 87.5 and 42.4 %, respectively; p < 0.0001). In a similar fashion, superior EFS was observed in patients with a NLR < 2 at the diagnosis compared with patients with a NLR a parts per thousand yen2 (5-year EFS rates were 88.4 and 41.8 %, respectively, p < 0.0001). This study suggests that NLR at the diagnosis is a simple, inexpensive, possible prognostic factor to assess clinical outcomes in MM patients.